Nippon India Pharma Fund - Growth is a Sector - Healthcare mutual fund scheme from Nippon Life India Asset Management Ltd. The fund was launched on 5 June 2004 and is managed by Kinjal Desai, Sailesh Raj Bhan, and Amber Singhania. As of 15 October 2026, the fund has an AUM of ₹9,166.40 Cr and its latest NAV is ₹538.68. The fund has a Very High Risk risk rating.
The fund allows minimum SIP of ₹100 and lumpsum investment starting from ₹5,000.
The fund primarily invests in Healthcare and its top holdings include Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Lupin Ltd, Cipla Ltd, and Dr Reddy's Laboratories Ltd. The fund has delivered 5.6% returns over the last 1 year, 15.4% annualised returns over 3 years, 11.6% annualised returns over 5 years, and 19.5% annualised returns since inception.
Nippon India Pharma Fund - Growth may be suitable for investors looking for Sector - Healthcare and who are comfortable with Very High Risk risk.






